Serum Testosterone And Dihydrotestosterone And Incidence And Progression Of Lower Urinary Tract Symptoms: Results From The Reduce Study

The REDUCE study, involving 3,009 asymptomatic and 2,145 symptomatic men, investigated whether elevated serum testosterone or dihydrotestosterone levels were risk factors for the incidence and progression of lower urinary tract symptoms (LUTS). The results showed no significant association between higher serum testosterone or dihydrotestosterone levels and the incidence of LUTS in asymptomatic men (P = .9, P = .4) or the progression of LUTS in symptomatic men (P = .9, P = .7). These findings were consistent across both the placebo and dutasteride treatment arms. The study concludes that serum androgens in middle-aged men are not linked to LUTS, challenging the hypothesis that increasing androgen levels contribute to the condition.